Condensed Consolidated Statements of Operations - (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 987,000	$ 8,000
Operating expenses:
Research and development	3,103,000	4,204,000
General and administrative	2,164,000	2,450,000
Total operating expenses	5,267,000	6,654,000
Operating loss	(4,280,000)	(6,646,000)
Other (expense) income – related party	(1,648,000)	(363,000)
Interest income	1,000	12,000
Interest expense		(168,000)
Loss before income taxes and noncontrolling interest	(5,927,000)	(7,165,000)
Income tax provision	15,000	0
Net loss before noncontrolling interest	(5,942,000)	(7,165,000)
Less: net loss attributable to noncontrolling interest	(1,701,000)	(2,441,000)
Net loss attributable to vTv Therapeutics Inc.	(4,241,000)	(4,724,000)
Net loss attributable to vTv Therapeutics Inc. common shareholders	$ (4,241,000)	$ (4,724,000)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.08)	$ (0.11)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	56,472,535	43,462,551